Related Experiment Video
Updated: Sep 13, 2025

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
Published on: February 5, 2018
Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites
Morgan I Coleman1, Mahfuz B Khan1, Erick Gbodossou2
1Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr. SW, Atlannta, GA 30310, USA.
Abstract:
Momordica balsamina, a plant traditionally used in African medicine, contains a 30 kDa protein, MoMo30, previously identified by our group as an anti-HIV agent that binds glycan residues on the gp120 envelope protein, thereby acting as an entry inhibitor. In this study, we investigated whether prolonged exposure to MoMo30 exerts selective pressure on HIV-1 and induces mutations in the viral envelope (env) gene. T-lymphocyte cells were infected with HIV-1NL4-3 and continuously treated with MoMo30 over a 24-day period. Viral RNA was isolated at regular intervals, and env genes were sequenced using the Illumina platform. RNA sequence variant calling was performed using iVar, which uses a frequency-based binomial test with a default allele frequency threshold of 3% and a minimum base quality of 20 and applies Bonferroni correction for multiple testing. The infectivity of the MoMo30-exposed virus was assessed using MAGI-CXCR4 cells, visualized by β-galactosidase staining, and compared to untreated controls. Statistical significance was determined via two-way ANOVA. MoMo30-treated HIV-1 exhibited multiple detrimental mutations in gp120 and gp41, including missense, nonsense, and frameshift changes. Notably, 32% of N-linked glycosylation sites were deleted in the treated virus, while no such changes were observed in controls. Functionally, the MoMo30-treated virus demonstrated a sixfold reduction in infectivity compared to untreated HIV-1NL4-3. These findings suggest that MoMo30 imposes genetic pressure on HIV-1NL4-3, selecting for mutations that reduce viral fitness.
Insights
The plant protein MoMo30, an anti-HIV agent, induces detrimental mutations in the HIV-1 envelope gene upon prolonged exposure. This genetic pressure reduces viral infectivity, suggesting a novel therapeutic strategy against HIV.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- Momordica balsamina contains MoMo30, a protein identified as an anti-HIV entry inhibitor.
- MoMo30 binds to glycan residues on the HIV-1 gp120 envelope protein.
Purpose of the Study:
- To investigate if prolonged exposure to MoMo30 induces selective pressure on HIV-1.
- To determine if MoMo30 causes mutations in the HIV-1 envelope (env) gene.
Main Methods:
- T-lymphocytes infected with HIV-1 NL4-3 were continuously treated with MoMo30 for 24 days.
- Viral RNA env genes were sequenced using Illumina, with variant calling via iVar.
- HIV infectivity was assessed using MAGI-CXCR4 cells and compared to controls.
Main Results:
- MoMo30-treated HIV-1 developed detrimental mutations in gp120 and gp41, including deletions in N-linked glycosylation sites.
- 32% of N-linked glycosylation sites were deleted in the treated virus.
- The MoMo30-treated virus showed a sixfold reduction in infectivity compared to controls.
Conclusions:
- MoMo30 exerts genetic pressure on HIV-1 NL4-3.
- This pressure selects for mutations that decrease viral fitness and infectivity.
- MoMo30 demonstrates potential as a therapeutic agent by compromising viral integrity.
Related Concept Videos
Protein Glycosylation
Glycosylation occurs in...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...

